NGR006 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by colorectal cancer CRC , previously treated with fluoropyrimidine, oxaliplatin and irinotecan based regimens.
Read time: 1 mins
Last updated:24th Jan 2007
Antitumour activity defined as Progression Free Survival.
|Study start date||2007-01-24|